Business UpdateMay 29, 2026, 07:32 AM
Adaptive Biotechnologies' clonoSEQ featured in 33 presentations at ASCO/EHA
AI Summary
Adaptive Biotechnologies announced its clonoSEQ test will be featured in 33 presentations, including one plenary and 14 oral presentations, at the ASCO Annual Meeting and EHA Congress. These presentations reinforce clonoSEQ's role as the gold standard for assessing depth of response, longitudinal disease monitoring, and MRD-guided treatment decision-making in hematologic oncology. The data highlights its broad incorporation into research and clinical practice across multiple myeloma, CLL, ALL, and lymphoma, with growing global momentum for MRD-guided care.
Key Highlights
- clonoSEQ test featured in 33 presentations at ASCO and EHA medical meetings.
- Presentations include one plenary session and 14 oral presentations.
- Data reinforces clonoSEQ as the gold standard for MRD assessment in hematologic oncology.
- Studies highlight clonoSEQ's broad incorporation in multiple myeloma, CLL, ALL, and lymphoma.
- CEPHEUS trial showed higher sustained MRD negativity with quadruplet regimen using clonoSEQ.
- VenetoSTOP trial demonstrated personalized venetoclax treatment duration based on uMRD5 status.
- clonoSEQ outperforms flow cytometry in detecting residual disease in Acute Lymphoblastic Leukemia.
- Growing global momentum for MRD-guided care, driven by biopharmaceutical investment.
Price Impact
More from ADPT